Recent developments in the discovery of novel antipsychotic agents modualating dopamine and serotonin receptors

Current Drug Targets

Volumn 14, Issue 8, 2013, Pages 899-918

  Li, Xin ^a   Ma, Shutao ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Arylpiperazines; Atypical antipsychotics; Butyrophenones; Dopamine and serotonin receptors; Schizophrenia; Tricycles

Indexed keywords

APOMORPHINE; ASENAPINE; BENZIMIDAZOLE DERIVATIVE; BENZOFURAN DERIVATIVE; BLONANSERIN; BUTYROPHENONE DERIVATIVE; CARIPRAZINE; CLOZAPINE; COUMARIN; DOPAMINE RECEPTOR; HALOPERIDOL; ILOPERIDONE; KETANSERIN; LOXAPINE; LURASIDONE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PIPERIDINE DERIVATIVE; RISPERIDONE; SEROTONIN RECEPTOR; ZIPRASIDONE;

ANIMAL BEHAVIOR; BINDING AFFINITY; CATALEPSY; DRUG DESIGN; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; NEUROTOXICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; TASK PERFORMANCE;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; HUMANS; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SCHIZOPHRENIA;

EID: 84881354961     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/13894501113149990007     Document Type: Review

References (94)

1. Jibson MD, Glick ID, Tandon R. Schizophrenia and Other Psychotic Disorders. Focus 2004; 2: 17-30.
2. Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT. Neurobiology of schizophrenia. Neuron 2006; 52: 139-53.
3. Lewis DA, Gonzalez-Burgos G. Pathophysiologically based treatment interventions in schizophrenia. Nat Med 2006; 12: 1016-22.
4. Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry 2007; 18: 39-60.
5. Crossley NA, Constante M, McGuire P, Power P. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry 2010; 196: 434-39.
6. Eyles DW, Avent KM, Stedman TJ, Pond SM. Two pyridinium metabolites of haloperidol are present in the brain of patients at post-mortem. Life Sci 1997; 60: 529-34.
7. Sikazwe DM, Li S, Mardenborough L, et al. Haloperidol: towards further understanding of the structural contributions of its pharmacophoric elements at D2-like receptors. Bioorg Med Chem Lett 2004; 14: 5739-42.
8. Bardin L, Auclair A, Kleven MS, et al. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics. Behav Pharmacol 2007; 18: 103-18.
9. Cuisiat S, Bourdiol N, Lacharme V, et al. Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities. J Med Chem 2007; 50: 865-76.
10. Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychoticsinduced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 2005; 20: 368-78.
11. Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275: 101-13.
12. Bricker B, Jackson T, Boateng B, Zhu XY, Ablordeppe, SY. Evaluation of the behavioral and pharmacokinetic profile of SYA013, a homopiperazine analog of haloperidol in rats. Pharmacol Biochem Behav 2012; 102: 294-301.
13. Lyles-Eggleston M, Altundas R, Xia J, et al. Design, synthesis, and evaluation of metabolism-based analogues of haloperidol incapable of forming MPP+-like species. J Med Chem 2004; 47: 497-508.
14. Tacke R, Popp F, Muller B, et al. Sila-haloperidol, a silicon analogue of the dopamine (D2) receptor antagonist haloperidol: synthesis, pharmacological properties, and metabolic fate. ChemMedChem 2008, 3: 152-64.
15. Ablordeppey SY, Borne RF. Detection of a neurotoxic quaternary pyridinium metabolite in the liver of haloperidol-treated rats. Pharmacol Biochem Behav 1993; 46: 739-44.
16. Subramanyam B, Rollema H, Woolf T, Castagnoli N. Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem Biophys Res Commun 1990; 166: 238-44.
17. Subramanyam B, Pond SM, Eyles DW, et al. Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol. Biochem Biophys Res Commun 1991; 181: 573-78.
18. Subramanyam B, Woolf T, Castagnoli N. Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite. Chem Res Toxicol 1991; 4: 123-28.
19. Lee T, Robichaud AJ, Boyle KE, et al. Novel, highly potent, selective 5-HT2A/D2 receptor antagonists as potential atypical antipsychotics. Bioorg Med Chem Lett 2003; 13: 767-70.
20. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989; 251: 238-46.
21. Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989; 25: 390-92.
22. Lowe III JA. Atypical Antipsychotics based on the D2/5-HT2 Ratio Hypothesis. Curr Med Chem 1994; 1: 50-60.
23. Fontenla JA, Osuna J, Rosa E, et al. Synthesis and atypical antipsychotic profile of some 2-(2-piperidinoethyl)benzocycloalkanones as analogues of butyrophenone. J Med Chem 1994; 37: 2564-73.
24. Cortizo L, Santana L, Ravina E, et al. Synthesis and antidopaminergic activity of some 3-(aminomethyl)tetralones as analogues of butyrophenone. J Med Chem 1991; 34: 2242-47.
25. Caro Y, Torrado M, Masaguer CF, et al. Chemoenzymatic synthesis and binding affinity of novel (R)-and (S)-3-aminomethyl-1-tetralones, potential atypical antipsychotics. Bioorg Med Chem Lett 2004; 14: 585-9.
26. Mewshaw RE, Silverman LS, Mathew RM, et al. Bridged gammacarbolines and derivatives possessing selective and combined affinity for 5-HT2 and D2 receptors. J Med Chem 1993; 36: 1488-95.
27. Alvarado M, Coelho A, Masaguer CF, et al. Synthesis and binding affinity of novel 3-aminoethyl-1-tetralones, potential atypical antipsychotics. Bioorg Med Chem Lett 2005; 15: 3063-66.
28. Caro Y, Torrado MA, Masaguer CF, et al. Chemoenzymatic synthesis and binding affinity of novel (R)-and (S)-3-aminomethyl-1-tetralones, potential atypical antipsychotics. Bioorg. Med. Chem. Lett. 2004; 14: 585-9.
29. Ravina E, Masaguer CF, Cid J, et al. Butyrophenone analogues: Synthesis of 2-methyl-3-ethyl-5-aminoethyl-4,5,6,7-tetrahydroindol-4-ones, and their affinities for d1, d2 and 5-ht2a receptors. Bioorg Med Chem Lett 1995; 5: 579-84.
30. Masaguer CF, Casariego I, Ravina E. Conformationally Restricted Butyrophenones with Mixed Dopaminergic (D2) and Serotoninergic (5-HT2A) Affinities. Synthesis of 5-Aminoethyl and 6-Aminomethyl-4-oxotetrahydroindoles as Potential Atypical Antipsychotics. Chem Pharm Bull 1999; 47: 621-32.
31. Masaguer CF, Raviña E, Loza I, Fontenla J. New cyclic butyrophenone derivatives in the indole series as potential atypical antipsychotics. A simple and practical synthesis of 6-aminomethyl tetrahydroindol-4-ones and their affinites for D2 and 5-HT2A receptors. Bioorg Med Chem Lett 1997; 7: 913-8.
32. Masaguer CF, Formoso E, Ravina E, et al. Butyrophenone analogues in the carbazole series: synthesis and determination of affinities at D2 and 5-HT2A receptors. Bioorg Med Chem Lett 1998; 8: 3571-6.
33. Masaguer CF, Ravina E, Fontenla JA, et al. Butyrophenone analogues in the carbazole series as potential atypical antipsychotics: synthesis and determination of affinities at D(2), 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Eur J Med Chem 2000; 35: 83-95.
34. Patani GA, LaVoie EJ. Bioisosterism: A Rational Approach in Drug Design. Chem Rev 1996; 96: 3147-76.
35. Kier LB, Hall LH. Bioisosterism: quantitation of structure and property effects. Chem Biodivers 2004; 1: 138-51.
36. Carro L, Ravina E, Dominguez E, et al. Synthesis and binding affinity of potential atypical antipsychotics with the tetrahydroquinazolinone motif. Bioorg Med Chem Lett 2009; 19: 6059-62.
37. Joyce JN, Millan MJ. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today 2005; 10: 917-25.
38. Casariego I, Masaguer CF, Raviña E. New CNS agent precursors. A simple and efficient route for synthesis of 6-aminomethyl-4,5,6,7-tetrahydrobenzofuran-4-ones as conformationally constrained butyrophenone analogues. Tetrahedron Lett 1997; 38: 5555-8.
39. Ravina E, Casariego I, Masaguer CF, et al. Conformationally constrained butyrophenones with affinity for dopamine (D(1), D(2), D(4)) and serotonin (5-HT(2A), 5-HT(2B), 5-HT(2C)) receptors: synthesis of aminomethylbenzo[b]furanones and their evaluation as antipsychotics. J Med Chem 2000; 43: 4678-93.
40. Brea J, Rodrigo J, Carrieri A, et al. New Serotonin 5-HT2A, 5-HT2B, and 5-HT2C Receptor Antagonists: Synthesis, Pharmacology, 3D-QSAR, and Molecular Modeling of (Aminoalkyl)benzo and Heterocycloalkanones. J Med Chem 2001; 45: 54-71.
41. Ravina E, Negreira J, Cid J, et al. Conformationally constrained butyrophenones with mixed dopaminergic (D(2)) and serotoninergic (5-HT(2A), 5-HT(2C)) affinities: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo-and-thienocycloalkanones as putative atypical antipsychotics. J Med Chem 1999; 42: 2774-97.
42. Tomic M, Kundakovic M, Butorovic B, et al. Pharmacological evaluation of 5-[2-[4-(2-methoxy-phenyl)-piperazin-1-yl]-ethyl]-1,3-dihydro-benzimidazol e-2-thione as a potential atypical antipsychotic agent. Pharmazie 2003; 58: 677-78.
43. Tomic M, Kundakovic M, Butorovic B, et al. Pharmacological evaluation of selected arylpiperazines with atypical antipsychotic potential. Bioorg Med Chem Lett 2004; 14: 4263-6.
44. Tomic M, Ignjatovic D, Tovilovic G, et al. Two new phenylpiperazines with atypical antipsychotic potential. Bioorg Med Chem Lett 2007; 17: 5749-53.
45. Andric D, Roglic G, Sukalovic V, Soskic V, Kostic-Rajacic S. Synthesis, binding properties and receptor docking of 4-halo-6-[2-(4-arylpiperazin-1-yl)ethyl]-1H-benzimidazoles, mixed ligands of D2 and 5-HT1A receptors. Eur J Med Chem 2008; 43: 1696-705.
46. Favor DA, Powers JJ, White AD, et al. 6-Alkoxyisoindolin-1-one based dopamine D2 partial agonists as potential antipsychotics. Bioorg Med Chem Lett 2010; 20: 5666-9.
47. Silver H. Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Expert Opin Pharmacother 2004; 5: 2053-58.
48. Rotella DP, McFarlane GR, Greenfield A, et al. Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia. Bioorg Med Chem Lett 2009; 19: 5552-5.
49. Singer JM, Barr BM, Coughenour LL, Gregory TF, Walters MA. 8-Substituted 3,4-dihydroquinolinones as a novel scaffold for atypical antipsychotic activity. Bioorg Med Chem Lett 2005; 15: 4560-63.
50. Gonzalez-Gomez JC, Santana L, Uriarte E, et al. New arylpiperazine derivatives with high affinity for alpha1A, D2 and 5-HT2A receptors. Bioorg Med Chem Lett 2003; 13: 175-8.
51. Wadenberg ML, Hertel P, Fernholm R, et al. Enhancement of antipsychotic-like effects by combined treatment with the alpha1-adrenoceptor antagonist prazosin and the dopamine D2 receptor antagonist raclopride in rats. J Neural Transm 2000; 107: 1229-38.
52. Butini S, Gemma S, Campiani G, et al. Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior. J Med Chem 2009; 52: 151-69.
53. John Murray P, Harrison LA, Johnson MR, et al. A novel series of arylpiperazines with high affinity and selectivity for the dopamine D3 receptor. Bioorg Med Chem Lett 1995; 5: 219-22.
54. Feenstra RW, De Moes J, Hofma JJ, et al. New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D(2)-receptor and serotonin 5-HT(1A)-receptor affinities. Bioorg Med Chem Lett 2001; 11: 2345-9.
55. Jones CA, McCreary AC. Serotonergic approaches in the development of novel antipsychotics. Neuropharmacology 2008; 55: 1056-65.
56. Neves G, Menegatti R, Antonio CB, et al. Searching for multitarget antipsychotics: Discovery of orally active heterocyclic Nphenylpiperazine ligands of D2-like and 5-HT1A receptors. Bioorg Med Chem 2010; 18: 1925-35.
57. Newman-Tancredi A, Assié MB, Leduc N, et al. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J of Neuropsychoph 2005; 8: 341-56.
58. Sukalovic V, Ignjatovic D, Tovilovic G, et al. Interactions of N-{[2-(4-phenyl-piperazin-1-yl)-ethyl]-phenyl}-2-aryl-2-ylacetamides and 1-{[2-(4-phenyl-piperazin-1-yl)-ethyl]-phenyl}-3-aryl-2-yl-ureas with dopamine D2 and 5-hydroxytryptamine 5HT(1A) receptors. Bioorg Med Chem Lett 2012; 22: 3967-72.
59. Asproni B, Pau A, Bitti M, et al. Synthesis and pharmacological evaluation of 1-[(1,2-diphenyl-1H-4-imidazolyl)methyl]-4-phenylpiperazines with clozapine-like mixed activities at dopamine D(2), serotonin, and GABA(A) receptors. J Med Chem 2002; 45: 4655-68.
60. Geneste H, Amberg W, Backfisch G, et al. Synthesis and SAR of highly potent and selective dopamine D3-receptor antagonists: variations on the 1H-pyrimidin-2-one theme. Bioorg Med Chem Lett 2006; 16: 1934-7.
61. Geneste H, Backfisch G, Braje W, et al. Synthesis and SAR of highly potent and selective dopamine D(3)-receptor antagonists: 1H-pyrimidin-2-one derivatives. Bioorg Med Chem Lett 2006; 16: 490-94.
62. Kiss B, Horvath A, Nemethy Z, et al. Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther 2010; 333(1): 328-40.
63. Tenjin T, Miyamoto S, Ninomiya Y, et al. Profile of blonanserin for the treatment of schizophrenia. Neuropsychiatr Dis Treat 2013; 9: 587-94.
64. Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 2010; 334(1): 171-81.
65. Bali A, Malhotra S, Dhir H, Kumar A, Sharma A. Synthesis and evaluation of 1-(quinoliloxypropyl)-4-aryl piperazines for atypical antipsychotic effect. Bioorg Med Chem Lett 2009; 19: 3041-4.
66. Bali A, Sharma K, Bhalla A, et al. Synthesis, evaluation and computational studies on a series of acetophenone based 1-(aryloxypropyl)-4-(chloroaryl) piperazines as potential atypical antipsychotics. Eur J Med Chem 2010; 45: 2656-62.
67. Srinivas P, Subramanian AR, Brust P, et al. Synthesis and preliminary pharmacological investigations of 1-(1,2-dihydro-2-acenaphthylenyl)piperazine derivatives as potential atypical antipsychotic agents in mice. Farmaco 1999; 54: 567-72.
68. Howard HR, Lowe JA, Seeger TF, et al. 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem 1996; 39: 143-8.
69. Lowe JA, Seeger TF, Nagel AA, et al. 1-Naphthylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem 1991; 34: 1860-6.
70. Sekhar KV, Rao VS, Vyas DR, Kumar MM. Synthesis and preliminary pharmacological evaluation of N-2-(4-(4-(2-substitutedthiazol-4-yl) piperazin-1-yl)-2-oxoethyl)acetamides as novel atypical antipsychotic agents. Bioorg Med Chem Lett 2008; 18: 6054-7.
71. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Expl Ther 1989; 251: 238-46.
72. Liao Y, Venhuis BJ, Rodenhuis N, et al. New (sulfonyloxy)piperazinyldibenzazepines as potential atypical antipsychotics: chemistry and pharmacological evaluation. J Med Chem 1999; 42: 2235-44.
73. Campiani G, Nacci V, Bechelli S, et al. New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure. J Med Chem 1998; 41: 3763-72.
74. Campiani G, Butini S, Gemma S, et al. Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. J Med Chem 2002; 45: 344-59.
75. Campiani G, Butini S, Fattorusso C, et al. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. J Med Chem 2004; 47: 143-57.
76. Campiani G, Butini S, Fattorusso C, et al. Novel atypical antipsychotic agents: rational design, an efficient palladiumcatalyzed route, and pharmacological studies. J Med Chem 2005; 48: 1705-8.
77. Klimas MT, Goldstein JM, Trainor DA, et al. Putative atypical antipsychotics with mixed dopaminergic (D1, D2) and serotonergic (5HT2) activity: The design evolution of ZD3638. Bioorg Med Chem Lett 1995; 5: 1795-800.
78. Fitzgerald PB. BL-1020, an oral antipsychotic agent that reduces dopamine activity and enhances GABA. Curr Opin Investig Drugs. 2010; 11(1): 92-100.
79. Shahid M, Walker GB, Zorn SH, Wong E. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009; 23(1): 65-73.
80. Bolos J, Anglada L, Gubert S, et al. 7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics. 2. Pharmacological profile of 7-[3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-piperidin-1-yl]propoxy]-3-(hydroxymeth yl)chromen-4-one (abaperidone, FI-8602). J Med Chem 1998; 41: 5402-9.
81. Chen Y, Xu X, Liu X, et al. Synthesis and Evaluation of a Series of 2-Substituted-5-Thiopropylpiperazine (Piperidine)-1, 3, 4-Oxadiazoles Derivatives as Atypical Antipsychotics. PLoS One 2012; 7: e35186.
82. Leysen JE, Janssen P, Gommeren W, Wynants J, Pauwels PJ, Janssen P. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol pharmacol. 1992; 41(3): 494-508.
83. Glick ID, Peselow ED. New antipsychotic agents. Prim Psychiatry. 2008; 15: 57-64.
84. Capasso A, Milano W. Paliperidone in the treatment of Schizophrenia: An overview. Curr Neurobiol 2012; 3(2): 133-50.
85. Homan EJ, Copinga S, Unelius L, et al. Synthesis and Pharmacology of the enantiomers of the potential atypical antipsychotic agents 5-OMe-BPAT and 5-OMe-(2,6-di-OMe)-BPAT. Bioorg Med Chem 1999; 7: 1263-71.
86. Pinna GA, Curzu MM, Sechi M, Chelucci G, Maciocco E. Synthesis and dopamine D2-like receptor binding affinity of substituted 5-phenyl-pyrrole-3-carboxamides. Farmaco 1999; 54: 542-50.
87. Diouf O, Carato P, Lesieur I, Rettori MC, Caignard DH. Synthesis and pharmacological evaluation of novel 4-(4-fluorobenzoyl)piperidine derivatives as mixed 5-HT1A/5-HT2A/D2 receptor ligands. Eur J Med Chem 1999; 34: 69-73.
88. Talaga P, Matagne A, Klitgaard H. Pharmacological evaluation of a diarylmethylene-piperidine derivative: a new potent atypical antipsychotic? Bioorg Med Chem Lett 2001; 11: 1313-6.
89. Garzya V, Forbes IT, Gribble AD, et al. Studies towards the identification of a new generation of atypical antipsychotic agents. Bioorg Med Chem Lett 2007; 17: 400-5.
90. Langlois X, Megens A, Lavreysen H, et al. Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia. J Pharmacol Exp Ther 2012; 342: 91-105.
91. Kaur H, Kumar S, Vishwakarma P, et al. Synthesis and antipsychotic and anticonvulsant activity of some new substituted oxa/thiadiazolylazetidinonyl/thiazolidinonylcarbazoles. Eur J Med Chem 2010; 45: 2777-83.
92. Sabb AL, Vogel RL, Kelly MG, et al. 1,2,5-Thiadiazole derivatives are potent and selective ligands at human 5-HT1A receptors. Bioorg Med Chem Lett 2001; 11: 1069-71.
93. Sadashiva CT, Chandra JN, Kavitha CV, et al. Synthesis and pharmacological evaluation of novel N-alkyl/aryl substituted thiazolidinone arecoline analogues as muscarinic receptor 1 agonist in Alzheimer's dementia models. Eur J Med Chem 2009; 44: 4848-54.
94. Kaur H, Kumar S, Chaudhary A, Kumar A. Synthesis and biological evaluation of some new substituted benzoxazepine and benzothiazepine as antipsychotic as well as anticonvulsant agents. Arab J of Chem 2012; 5: 271-83.